Centaurus Financial’s ProQR Therapeutics PRQR Stock Holding History

Centaurus Financial’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,500	Closed	-$11K	–	1653
2018 Q2	$11K	Buy	+1,500	New	+$7.56K	﹤0.01%	1523

Other funds holding PRQR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Centaurus Financial's PRQR Position: Q3 2018 in Review

Centaurus Financial sold out of ProQR Therapeutics (PRQR) in Q3 2018, closing a stake of 1,500 shares — an estimated $11K sold.

Centaurus Financial first reported a position in PRQR in Q2 2018 and held it in 1 quarter. The position peaked at $11K in Q2 2018. 34 funds tracked by Wall St. Rank hold PRQR as of Q3 2018.

Centaurus Financial reported no remaining ProQR Therapeutics position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 1,500 ProQR Therapeutics shares in Q3 2018, an estimated $11K.
Centaurus Financial first reported a position in ProQR Therapeutics in Q2 2018 and held it in 1 quarter.
Centaurus Financial's ProQR Therapeutics position peaked at $11K in Q2 2018.
34 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.